An observational study in MIRAS, Testicular Abnominalies and Undescended Testes, sponsored by Dr. Mevlüt Keleş. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 3 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Dr. Mevlüt Keleş · Observational
Background: Undescended testicles (UDTs) are common in male infants. Untreated UDT poses risks such as infertility (IF), testicular cancer (TC), and testicular torsion (TT). Retractile testicles (RTs) sporadically ascend from the scrotum. UDT requires early surgical correction, whereas RT requires only periodic follow-up. Differentiating these conditions is challenging, making clinical biomarkers potentially useful. The aim of our study was to examine the use of miRNAs, which are difficult to differentiate, as biomarkers in the differential diagnosis of UDT and RT.
Methods: This prospective study included 10 boys with UDT (operated), 9 with RT (followed), and 9 controls. Parent consent and serum samples were collected to evaluate miR-210, miR-34c, and miR-449a expression via real-time PCR. For group comparisons, one-way ANOVA was used for parametric data, and the Kruskal-Wallis test was used for nonparametric data, followed by the Dunn-Bonferroni correction for post hoc multiple comparisons. Spearman's rank correlation coefficient was used to analyse correlations. A p value \< 0.05 was considered significant.
Introduction Undescended testicles (UDTs) are the most common congenital male malformation, affecting 1.0-4.6% of term infants and up to 45% of preterm infants [1]. UDT can be congenital or acquired; spontaneous descent in congenital cases is rare after six months [2]. Untreated UDT beyond one year of age leads to interstitial fibrosis, degenerated spermatogenesis, and increased infertility risk [3-5]. Furthermore, untreated UDTs carry risks of testicular cancer (TC) and enhanced testicular torsion (TT). Early diagnosis and treatment are crucial to prevent these complications.
Differentiating true underscended testicles (UDTs) from retractile testicles (RTs) is clinically challenging. True UDT involves a consistently empty scrotum, with testicles never descending. Conversely, RTs can spontaneously descend or be manually reduced, although they may reascend. Treatment for RT depends on the time spent outside the scrotum. Misdiagnosing UDT as RT risks delayed treatment and inevitable complications. Thus, reliable indicators for distinguishing UDTs and RT are crucial.
MicroRNAs (miRNAs) are \~22-nucleotide noncoding RNAs that posttranscriptionally regulate gene expression [6]. MiRNAs are known to regulate spermatogenesis (SP), early embryonic development, sperm function, and fertilization in various species [7]. Given the expected SP disruption in true UDTs, the UDT-miRNA relationship has been explored. Studies have shown altered miRNA levels in UDT: miR-210 is upregulated [8], whereas miR-449a and miR-34c are downregulated [9-11]. Critically, data on miRNA changes in retractile testicle (RT) cases are currently lacking. Theoretically, the SP is not expected to be disrupted at RT. Thus, miRNA alterations, reflecting SP status, could differentiate RT from UDT, guiding surgical versus follow-up decisions. This study compared miRNA changes across UDT, RT, and normal control groups prospectively.
2.2. Patient population Initially, 10 boys with undescended testicles (UDTs), 10 with retractile testicles (RTs), and 10 healthy volunteers (controls) from our urology clinic (dates between March 2022 and March 2023) were enrolled. However, one RT patient and one control patient were excluded because of parental refusal for blood sampling. Only palpable (unilateral or bilateral) UDT cases were included, excluding nonpalpable types. To ensure accurate RT diagnosis, initial physician examinations were performed in three positions (supine, semisupine, standing), followed by a 1-month parental examination (twice daily). Only RT patients whose testicles spent >50% of their time in the scrotum were included. The exclusion criteria also included prior inguinal/scrotal surgery, defective datasets, or unsuitable serum samples.
2.3. Collection of patient data and control samples Detailed patient histories, physical examinations, and routine biochemical tests were performed. UDT blood samples were collected presurgery to prevent misinterpretation. Blood from all the groups was collected in 5 mL biochemistry tubes and centrifuged at 3000 rpm for 10 minutes. The resulting particle-free serum was transferred to 1.5 mL tubes and stored at -80°C until analysis.
2.4. Validation of the expression levels of miR-210, miR-449a and miR-34c via real-time PCR Serum samples from the urology clinic were subjected to RNA isolation via the Quick-cfRNA™ Serum \& Plasma Kit (Zymo Research). The extracted miRNA was reverse transcribed into cDNA via the miRNA All-In-One cDNA Synthesis Kit (ABMGood). cDNA quality and quantity were assessed spectrophotometrically with a BioSpec-nano instrument (Shimadzu) before real-time PCR. miRNA expression analysis was performed via a Rotor Gene Q (Qiagen) instrument. The levels of miR-210, miR-449a, and miR-34c were quantified with ready-to-use primers and BlasTaq™ 2X qPCR MasterMix (ABMGood).
2.5. Statistical analysis Data normality was assessed via the Shapiro-Wilk test, and variance equality was assessed via Levene's test. Descriptive statistics are presented as the means ± SDs for parametric data and medians (IQRs) and means (ranks) for nonparametric data. For group comparisons, one-way ANOVA was used for parametric data, and the Kruskal-Wallis test was used for nonparametric data, followed by the Dunn-Bonferroni correction for post hoc multiple comparisons. Spearman's rank correlation coefficient was used to analyse correlations. Statistical significance was set at p \< 0.05.
miRNA expression was quantified via qRT-PCR via Ct (crossing point) values and normalized to RNU6B_13. Relative miRNA expression levels were compared among all groups via the 2-ΔCt method and calculated as 2Ct (target gene) - Ct (reference gene). All the statistical analyses were performed via IBM SPSS v28 (IBM Inc., Chicago, IL, USA).
40 studies on the registry are indexed under Cryptorchidism; 14 are open to participants now.
This study's enrollment of 28 is below the median of 100 across 14 observational studies indexed under Cryptorchidism.
Browse Cryptorchidism studies →This is the only study on the registry with Dr. Mevlüt Keleş as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Control group: Healthy kids with both testes in scrotum. Undescended testis group: Kids with unilateral palpable undescended testis or bilateral palpable testes.
Recractile testis group: Kids under monitorisation for unilateral retractile testis or bilateral retractile testes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Undescended testicle cases whose miRNA levels investigated
Diagnostic Test: miRNA
Retractile testicle cases whose miRNA levels investigated
Diagnostic Test: miRNA
Healthy kids with testes in the scrotum whose miRNA levels investigated
Diagnostic Test: miRNA
miR-34c , miR-210 , miR-449a levels investigated.
miRNA levels
2Ct (target gene) - Ct (reference gene)
Time frame: Within study enrollement
miRNA changes
Differentiation of miRNA levels in three arms
Time frame: Rapid miRNA levels at study enrollement time.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.